Results 101 to 110 of about 13,362 (238)

NEUROLEPTIC MALIGNANT SYNDROME: A CASE REPORT [PDF]

The neuroleptic malignant syndrome is a rare but potentially fatal complication of neuroleptic administration. Many clinicians may not be familiar with this complication.
C. N. Chin, C. N. Chin
core  

G Protein‐Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers

MedComm, Volume 6, Issue 10, October 2025.
G protein‐coupled receptors (GPCRs) are the dynamic protein family in the human genome. GPCR dysregulation aids in the advancement of cancer through increased migration, survival, and proliferation. Novel treatments that target GPCR signaling include orthosteric ligands, biased receptor mutants, PROTACs, and antibody–drug conjugates.
Inamu Rashid Khan, Sana Khurshid, Saud Almawash, Rakesh Kumar, Ammira S. Al‐Shabeeb Akil, Ajaz A. Bhat, Muzafar A. Macha   +6 more
wiley   +1 more source

Gene and RNA Editing: Revolutionary Approaches to Treating Diseases

MedComm, Volume 6, Issue 10, October 2025.
The image illustrates gene editing technologies: DNA editing using CRISPR–Cas9 and RNA editing via Cas13d, with their clinical applications and ethical risks. DNA editing allows precise gene modifications for conditions like amyotrophic lateral sclerosis [ALS] and Huntington's disease, while RNA editing supports multiplexed modifications.
Jia‐Mei Li, Jie Huang, Yan Liao, Ting Hu, Chang‐Li Wang, Wang‐Zheqi Zhang, Chen‐Wei Huang   +6 more
wiley   +1 more source

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN

Obesity, Volume 33, Issue 10, Page 1873-1885, October 2025.
ABSTRACT Objective SURMOUNT‐MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD. Methods This Phase 3b, multicenter, randomized, parallel‐arm, double‐blinded, placebo‐controlled, 52 ...
Deborah B. Horn, Louis J. Aronne, Sean Wharton, Harold E. Bays, Elisa Gomez‐Valderas, Avigdor D. Arad, Palash Sharma, Julia P. Dunn, Cagri Senyucel, Clare J. Lee   +9 more
wiley   +1 more source

Fever and altered consciousness are not always equal to central nervous system infection: neuroleptic malignant syndrome in a 15-year-old girl

The Turkish Journal of Pediatrics, 1996
Neuroleptic malignant syndrome, the most serious and potentially fatal side effect of neuroleptics, is characterized by altered consciousness, extrapyramidal symptoms, hyperthermia, elevated plasma creatine phosphoidnase and leukocytosis.
F Unal, S Hizli, H Ozyürek, B Sonuvar
doaj  

Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms

Pharmacology Research &Perspectives, Volume 13, Issue 5, October 2025.
A multi‐targeted antidepressant with strong preclinical anticancer activity, sertraline represents a candidate for therapeutic repurposing. ABSTRACT Drug repurposing offers a cost‐effective and time‐efficient strategy for identifying new cancer therapies. Sertraline, a widely prescribed selective serotonin reuptake inhibitor (SSRI), has shown promising
Ciara B. Blum, McCarlie‐Jayne Dohrmann, Lucia McCarthy, Milli McMenamin, Liam A. O'Callaghan   +4 more
wiley   +1 more source

Neuroleptic malignant syndrome: the diagnostic dilemma

Open Journal of Psychiatry and Allied Sciences, 2016
Neuroleptic malignant syndrome (NMS) is a life-threatening, often fatal idiosyncratic reaction to neuroleptic or other drug therapies that antagonise the central dopaminergic neurotransmission. The clinical presentation of NMS is very heterogeneous.
Ivana Stasevic Karlicic, Jelena Djordjevic, Milena Stasevic, Slavica Djukic Dejanovic, Dragan Pavlovic, Slobodan Jankovic   +5 more
doaj   +1 more source

Neuroleptic malignant syndrome: need for early diagnosis and therapy [PDF]

, 2006
Background: Neuroleptic Malignant Syndrome (NMS) is a medical entity that has received little attention in the clinical settings in Pakistan. The aim of our study was to review the predisposing factors, outcomes and characteristics of in-patients ...
Kamal, Ayeesha, Khan, Humaira M., Khealani, Bhojo, Sheerani, Mughis, Syed, Nadir A., Wasay, Mohammad   +5 more
core   +1 more source

Adolescents With Severe Obesity Had an Increased Risk of Reporting Symptoms That Indicated They Had Major Depression

Acta Paediatrica, Volume 114, Issue 10, Page 2603-2611, October 2025.
ABSTRACT Aim This study aimed to compare the severity of depressive symptoms of Hong Kong adolescents with and without obesity and to explore the correlates of depressive symptoms using Patient Health Questionnaire‐9 (PHQ‐9). Methods Participants were recruited from the Paediatric Weight Control Clinic of Queen Mary Hospital or mainstream secondary ...
Geoffrey Chek‐Fei Yu, Ka‐Man Yip, Wilfred Hing‐Sang Wong, Queenie Wing‐Shan See   +3 more
wiley   +1 more source

THE ROLE OF CYP2D6 AND TAQI A POLYMORPHISMS IN MALIGNANT NEUROLEPTIC SYNDROME: TWO CASE REPORTS WITH THREE EPISODES [PDF]

, 2010
Malignant neuroleptic syndrome (MNS) is a serious and potentially fatal side-effect of neuroleptic treatment. Beside antipsychotic drugs, other psychotropic drugs such as antidepressants and lithium carbonate can cause this life threatening sideeffect ...
Alma Mihaljević-Peleš, Ante Silić, Maja Živković, Marina Šagud, Mate Mihanović   +4 more
core   +1 more source